Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.61 (market cap $115.19B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 15.3× Spyre Therapeutics Inc. Common Stock's market cap, and iShares 0 3 Month Treasury Bond ETF is more actively traded (18,240,700 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 51 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SGOV | SYRE | |
|---|---|---|
Market Cap | $115.19B | $7.52B |
Volume | 18,240,700 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $108.92 |
52-Week Low | $100.28 | $22.18 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52 with no price change. The technical outlook is bearish, driven by moving averages, while oscillators are neutral. Recent corporate actions include scheduled dividend payments through late 2026. Market sentiment is influenced by a significant bond selloff and rising Treasury yields, with institutional activity showing a reduction in holdings by Envestnet Asset Management.
The outlook for SGOV is cautious amid a challenging bond market environment. Investment opportunities lie in its short-duration Treasury exposure during rate volatility, but risks include prolonged high interest rates and inflation pressures. Investors should weigh the ETF's stability against macroeconomic headwinds impacting fixed income.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
